3,4-methylenedioxyamphetamine has been researched along with 3,4-methylenedioxyethamphetamine in 150 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (10.00) | 18.7374 |
| 1990's | 64 (42.67) | 18.2507 |
| 2000's | 49 (32.67) | 29.6817 |
| 2010's | 20 (13.33) | 24.3611 |
| 2020's | 2 (1.33) | 2.80 |
| Authors | Studies |
|---|---|
| Clare, BW | 1 |
| Chei, DM; Foltz, RL; Lim, HK; Zeng, S | 1 |
| Ensslin, M; Gouzoulis, E; Hermle, L; Kovar, A; Steiger, A | 1 |
| Axt, KJ; Molliver, ME; Mullen, CA | 1 |
| Battaglia, G; de Souza, EB; Kuhar, MJ; Sharkey, J | 1 |
| Boja, JW; Schechter, MD | 2 |
| Blanke, RV; Fitzgerald, RL; Glennon, RA; Narasimhachari, N; Rosecrans, JA; Yousif, MY | 1 |
| Blanke, RV; Fitzgerald, RL; Poklis, A | 1 |
| Gibb, JW; Hanson, GR; Johnson, M | 2 |
| Barrett, JE; Hoffmann, SM; Nader, MA | 1 |
| Glennon, RA; Misenheimer, BR | 1 |
| Braff, DL; Geyer, MA; Mansbach, RS | 1 |
| Bost, RO; Dowling, GP; McDonough, ET | 1 |
| Gibb, JW; Hanson, GR; Johnson, M; Stone, DM | 1 |
| Schmidt, CJ | 1 |
| DeLanney, LE; Finnegan, KF; Irwin, I; Langston, JW; Nichols, DE; Ricaurte, GA | 1 |
| Glennon, RA; Patrick, G; Yousif, M | 1 |
| Geyer, MA; Gold, LH; Koob, GF | 1 |
| Laverty, R; Logan, BJ; Sanderson, WD; Yee, YB | 1 |
| Peroutka, SJ; Pierce, PA | 1 |
| Schechter, MD | 1 |
| Hardern, R; Tehan, B | 1 |
| Harvey, JA; McMaster, SE; Romano, AG | 1 |
| Kelly, PA; McBean, DE; Olverman, HJ; Ritchie, IM; Sharkey, J | 1 |
| George, WJ; Michel, RE; Rege, AB | 1 |
| Nakahara, Y; Shimamine, M; Takahashi, K | 1 |
| Molliver, ME; Series, HG | 1 |
| Borchardt, D; Gouzoulis, E; Hermle, L | 1 |
| De Man, RA; Ijzermans, JN; Metselaar, HJ; Tilanus, HW | 1 |
| Bodenham, A; Hardern, R; Tehan, B | 1 |
| Berger, M; Borchardt, D; Fünfgeld, M; Gouzoulis, E; Hermle, L; Kovar, KA; Oepen, G; Spitzer, M | 1 |
| Borchardt, D; Gouzoulis, E; Hermle, L; Kovar, KA; Spitzer, M | 1 |
| Gouzoulis, E; Hermle, L; Kovar, KA; Rupp, A; von Bardeleben, U | 1 |
| Iwersen, S; Schmoldt, A | 1 |
| Korten, JJ; Roebroek, RM | 1 |
| Clark, JC; Forrest, AR; Milroy, CM | 1 |
| Cox, DE; Williams, KR | 1 |
| Brown, ER; Jarvie, DR; Simpson, D | 1 |
| Fineschi, V; Masti, A | 1 |
| Tucker, G | 1 |
| Merrill, J | 1 |
| Saunders, N | 1 |
| King, LA; Winstock, AR | 1 |
| Dalgarno, P; Shewan, D | 1 |
| Ryan, JM; Stell, JM | 1 |
| Kauert, G; Röhrich, J | 1 |
| Andries, S; Bossaert, L; Demey, HE; Heytens, L; Jorens, PG; Ricaurte, GA; Schepens, PJ | 1 |
| Balanzó, X; Camí, J; de la Torre, R; Rafel, J | 1 |
| Ensslin, HK; Gouzoulis, E; Hermle, L; Kovar, KA; Maurer, HH | 1 |
| Keogh, G; Trenerry, VC; Vandepeer, J | 1 |
| Ensslin, HK; Kovar, KA; Maurer, HH | 1 |
| Burroughs, A; Dhillon, A; Fidler, H; Gertner, D | 1 |
| Gouzoulis-Mayfrank, E; Hermle, L; Kovar, KA; Sass, H | 1 |
| Barni Comparini, I; Centini, F; Masti, A | 1 |
| Assion, HJ; Heinemann, F | 1 |
| Kikura, R; Mieczkowski, T; Nakahara, Y; Tagliaro, F | 1 |
| Barrio Anta, G; de la Fuente de Hoz, L; Rodríguez Arenas, MA; Sánchez Payá, J; Vicente Orta, J | 1 |
| Michalodimitrakis, MN; Patsalis, AN; Tsatsakis, AM | 1 |
| Hall, AP | 1 |
| Sadeghipour, F; Veuthey, JL | 1 |
| Bogusz, MJ | 1 |
| Bollani, T; Favretto, D; Garofano, L; Guidugli, F; Patri, P; Santoro, M; Traldi, P | 1 |
| Arimany, J; Borondo, JC; Medallo, J; Pujol, A; Valverde, JL; Vingut, A | 1 |
| Dirnhofer, R; Keller, T; Miki, A; Regenscheit, P; Schneider, A; Tsuchihashi, H | 1 |
| Kovar, KA | 1 |
| Brunnenberg, M; Gouzoulis-Mayfrank, E; Kovar, KA; Lindenblatt, H | 1 |
| Baker, GB; Bourin, M; Hegadoren, KM | 1 |
| Gouzoulis-Mayfrank, E; Habermeyer, E; Hermle, L; Kovar, KA; Kunert, HJ; Lindenblatt, H; Sass, H; Spitzer, M; Thelen, B | 1 |
| Arning, C; Büll, U; Gouzoulis-Mayfrank, E; Hermle, L; Kovar, KA; Sabri, O; Sass, H; Schreckenberger, M; Spitzer, M; Thelen, B | 1 |
| Colado, MI; Esteban, B; Granados, R; Green, AR; O'Shea, E | 1 |
| Felgenhauer, N; Zilker, T | 1 |
| Cody, JT; Hensley, D | 1 |
| Centini, F; Fineschi, V; Mazzeo, E; Turillazzi, E | 1 |
| Arning, C; Buell, U; Gouzoulis-Mayfrank, E; Kaiser, HJ; Sabri, O; Sass, H; Schreckenberger, M; Wagenknecht, G; Zeggel, T; Zimny, M | 1 |
| Aguirre, N; Barrionuevo, M; Del Río, JD; Lasheras, B | 1 |
| Allen, DL; Oliver, JS | 1 |
| Krogh, M; Rasmussen, KE; Ugland, HG | 1 |
| Dawson, M; Kannangara, GS; Lee, GS; Taylor, RC; Wilson, MA | 1 |
| Clauwaert, KM; De Leenheer, AP; De Letter, EA; Lambert, WE; Van Bocxlaer, JF; Van Calenbergh, S | 1 |
| Gresham, GL; Groenewold, GS; Olson, JE | 1 |
| Brunnenberg, M; Kovar, KA | 1 |
| Gudelsky, GA; Vorhees, CV; Wallace, TL | 1 |
| Mirken, B | 1 |
| Boland, G; Kelly, JP; O'Boyle, KM; O'Loinsigh, ED | 1 |
| Campíns-Falcó, P; Herráez-Hernández, R; Verdú-Andrés, J | 1 |
| Buechler, J; Franke, B; Grön, G; Hermle, L; Kovar, KA; Schwab, M; Spitzer, M; Walter, H; Wunderlich, AP | 1 |
| Clauwaert, KM; De Leenheer, AP; Van Bocxlaer, JF | 1 |
| Brehm, G; Sägmüller, B; Schneider, S; Schwarze, B | 1 |
| Gouzoulis-Mayfrank, E; Heekeren, K; Kovar, KA; Maier, S; Sass, H; Spitzer, M; Thelen, B | 1 |
| Barnett, DA; Ells, B; Guevremont, R; McCooeye, MA; Mester, Z; Purves, RW | 1 |
| Kovar, KA; Mayerhofer, A; Meyer, A; Schmidt, WJ | 1 |
| Broening, HW; Fukumura, M; McCrea, AE; Moran, MS; Morford, LL; Rock, SL; Vorhees, CV; Wallace, TL; Williams, MT; Wood, SL | 1 |
| Cole, JC; Sumnall, HR | 1 |
| Cooper, DP; De Boeck, G; De Bruijn, EA; Maes, RA; Morris, M; Samyn, N; Wood, M | 1 |
| Kovar, KA; Lebsanft, HB; Mayerhofer, A; Schmidt, WJ | 1 |
| Buechler, J; Fischer, B; Grön, G; Hermle, L; Kovar, KA; Marx, C; Mikus, G; Schwab, M; Spitzer, M | 1 |
| Cleary, L; Docherty, JR | 1 |
| Parrott, AC | 1 |
| Katagi, M; Miki, A; Shima, N; Tsuchihashi, H | 1 |
| Freudenmann, RW; Spitzer, M | 1 |
| da Costa, JL; da Matta Chasin, AA | 1 |
| Jacobs, A; Jemionek, J; Lesser, D; Paul, BD; Searles, DA | 1 |
| Belzung, C; Bodard, S; Chalon, S; Galineau, L; Guilloteau, D; Kodas, E | 1 |
| Bronselaer, K; De Feyter, K; De Munnynck, K; Sabbe, M; Smets, G; Van de Voorde, W | 1 |
| de Boeck, G; Kraemer, T; Lamers, CT; Maurer, HH; Peters, FT; Riedel, WJ; Samyn, N | 1 |
| Grubwieser, P; Libiseller, K; Pavlic, M; Rabl, W | 1 |
| Bouche, MP; Casteele, SR; Van Bocxlaer, JF | 1 |
| Carney, B; Gillespie, J; Mc Fadden, K; O'Driscoll, D | 1 |
| Bexis, S; Docherty, JR | 1 |
| Corkery, J; Deluca, P; Ghodse, AH; Oyefeso, A; Schifano, F | 1 |
| Johansen, SS; Olsen, KH; Rasmussen, LB | 1 |
| Blessing, WW; Ootsuka, Y; Zilm, A | 1 |
| Abraham, TT; Huestis, MA; Pirnay, SO | 1 |
| Martins, LF; Ramaekers, JG; Samyn, N; Wennig, R; Yegles, M | 1 |
| Cody, JT; Phelix, CF; Valtier, S | 1 |
| Chèze, M; Deveaux, M; Lhermitte, M; Martin, C; Pépin, G | 1 |
| Maurer, HH; Mueller, M; Peters, FT; Ricaurte, GA | 1 |
| Huestis, MA; Kolbrich, EA; Lowe, RH | 1 |
| Irvine, RJ; Jaehne, EJ; Salem, A | 1 |
| de Ruiter, A; Hritz, J; Oostenbrink, C | 1 |
| Cheong, JC; In, MK; Jin, C; Kim, JY; Ko, BJ; Lee, SK; Yoo, HH | 1 |
| Maurer, HH; Meyer, MR; Peters, FT | 1 |
| Kamata, HT; Kamata, T; Katagi, M; Miki, A; Mori, Y; Shima, N; Tsuchihashi, H; Zaitsu, K | 1 |
| Maurer, HH; Meyer, MR | 1 |
| Abraham, TT; Barnes, AJ; Goodwin, RS; Gorelick, DA; Huestis, MA; Kolbrich Spargo, EA; Lowe, RH; Milman, G; Pirnay, SO | 1 |
| Hritz, J; Oostenbrink, C; Santos, R | 1 |
| Awad, T; Belal, T; Clark, CR; DeRuiter, J; Maher, HM | 1 |
| Buchanan, T; Gates, J; Heffernan, T; Ling, J; Owen, L; Parrott, AC; Rodgers, J; Scholey, AB; Stough, C; Swan, P | 1 |
| Blacik, LJ; Kazarian, CM; Ntamack, AG; Romberg, RW; Snyder, JJ; Welsh, ER | 1 |
| Maldonado Adrian, C; McCann, UD; Mueller, M; Ricaurte, GA; Yuan, J | 1 |
| Chen, BH; Chen, PH; Lee, HH; Lee, JF; Lin, SY | 1 |
| Baylor, MR; Bynum, ND; Lewallen, CM; Mitchell, JM; Ropero-Miller, JD; Stout, PR | 1 |
| Hara, K; Hasegawa, C; Kumazawa, T; Lee, XP; Sato, K; Seno, H; Suzuki, O; Uchigasaki, S | 1 |
| Galceran, MT; Huerta-Fontela, M; Pineda, O; Ventura, F | 1 |
| Maurer, HH; Meyer, MR; Schwaninger, AE; Zapp, J | 1 |
| Gudelsky, GA; Johnson, BN; Weber, GF; Yamamoto, BK | 1 |
| Borrell, JI; Camarasa, J; Cristóbal-Lecina, E; Escubedo, E; García-Ratés, S; Llabrés, S; Luque, FJ; Pubill, D; Riera, A | 1 |
| Baritussio, A; Bigler, L; Calistri, A; Fabris, F; Ha, HR; Mirazimi, A; Munegato, D; Palù, G; Parolin, C; Salata, C | 1 |
| Covaci, A; Kinyua, J; Mardal, M; Meyer, MR; Miserez, B; Ramin, P; Van Nuijs, AL | 1 |
| Datye, A; Jiang, Y; Kauffman, AC; Nakazawa, KH; Piotrowski-Daspit, AS; Saltzman, WM | 1 |
| Blanes, L; Bordin, DM; de Campos, EG; De Martinis, BS; Doble, P; Ishikawa, AA | 1 |
| Murnane, KS | 1 |
| Fatehi, M; Haw, CS; Heran, MKS; Nugent, JP | 1 |
| Browne, G; McGettigan, S; Ronan, GP; Ronan, N | 1 |
| Burgueño, MJ; Castro, MÁ; Mateos-Campos, R; Sánchez, S | 1 |
| Angenoorth, TJF; Brandt, SD; Holy, M; Maier, J; Niello, M; Sitte, HH; Stankovic, S | 1 |
| Mafi, M; Mortaheb, HR; Nozaeim, AA; Tavasoli, A | 1 |
10 review(s) available for 3,4-methylenedioxyamphetamine and 3,4-methylenedioxyethamphetamine
| Article | Year |
|---|---|
Hyperthermia associated with 3,4-methylenedioxyethamphetamine ('Eve').
Topics: 3,4-Methylenedioxyamphetamine; Adult; Designer Drugs; Fever; Humans; Male; Poisoning; Substance-Related Disorders | 1993 |
[Significance of historical and current hallucinogenic research in psychiatry].
Topics: 3,4-Methylenedioxyamphetamine; Adult; Arousal; Designer Drugs; Dose-Response Relationship, Drug; Forecasting; Hallucinations; Hallucinogens; Humans; Mescaline; Middle Aged; Psychiatric Status Rating Scales; Psychoses, Substance-Induced | 1993 |
[Entactogenic drugs "ecstasy" (MDMA), "eve" (MDE) and other ring-substituted methamphetamine derivatives. A new class of substances among illegal designer drugs?].
Topics: 3,4-Methylenedioxyamphetamine; Animals; Designer Drugs; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Risk Factors; Substance Withdrawal Syndrome; Substance-Related Disorders | 1996 |
MDEA related death in Crete: a case report and literature review.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Designer Drugs; Fatal Outcome; Greece; Humans; Male | 1997 |
Chemistry and pharmacology of hallucinogens, entactogens and stimulants.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Brain; Central Nervous System Stimulants; Hallucinogens; Humans; Mescaline; N-Methyl-3,4-methylenedioxyamphetamine; Structure-Activity Relationship | 1998 |
3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Designer Drugs; Dopamine Uptake Inhibitors; Hallucinogens; Humans | 1999 |
[Poisoning with amphetamines and designer drugs].
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Designer Drugs; Drug Overdose; Humans; Illicit Drugs; Internal Medicine; N-Methyl-3,4-methylenedioxyamphetamine; Serotonin Syndrome; Substance-Related Disorders | 1999 |
Altered states: the clinical effects of Ecstasy.
Topics: 3,4-Methylenedioxyamphetamine; Brain; Clinical Trials as Topic; Cognition Disorders; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Substance-Related Disorders | 2003 |
The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA).
Topics: 3,4-Methylenedioxyamphetamine; Animals; Drug Administration Schedule; Drug Interactions; Europe; Hallucinogens; Humans; Illicit Drugs; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Nervous System Diseases; Neurotoxins; North America | 2004 |
Serotonin 2A receptors are a stress response system: implications for post-traumatic stress disorder.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Brain; Cues; Gene Expression; Gene Expression Regulation; Humans; Learning; Receptor, Serotonin, 5-HT2A; Serotonin; Stress Disorders, Post-Traumatic; Stress, Physiological | 2019 |
10 trial(s) available for 3,4-methylenedioxyamphetamine and 3,4-methylenedioxyethamphetamine
| Article | Year |
|---|---|
Sleep EEG effects of 3,4-methylenedioxyethamphetamine (MDE; "eve") in healthy volunteers.
Topics: 3,4-Methylenedioxyamphetamine; Administration, Oral; Adult; Double-Blind Method; Electroencephalography; Female; Humans; Male; Polysomnography; Sleep Stages; Sleep, REM | 1992 |
Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents?
Topics: 3,4-Methylenedioxyamphetamine; Adult; Double-Blind Method; Female; Humans; Male; Mental Disorders; Middle Aged; Psychiatric Status Rating Scales; Psychological Tests; Reference Values | 1993 |
Neuroendocrine and cardiovascular effects of MDE in healthy volunteers.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Blood Pressure; Designer Drugs; Double-Blind Method; Heart Rate; Hemodynamics; Hormones; Humans; Male; Middle Aged; Polysomnography | 1993 |
Quantitation of N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma by high-performance liquid chromatography and fluorescence detection.
Topics: 3,4-Methylenedioxyamphetamine; Chromatography, High Pressure Liquid; Designer Drugs; Humans; Reference Values; Spectrometry, Fluorescence | 1998 |
Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study.
Topics: 3,4-Methylenedioxyamphetamine; Acute-Phase Reaction; Adult; Aged; Autonomic Agents; Central Nervous System Stimulants; Double-Blind Method; Female; Hallucinogens; Humans; Male; Methamphetamine; Middle Aged; Neurosecretory Systems; Psilocybin; Psychopathology | 1999 |
Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG.
Topics: 3,4-Methylenedioxyamphetamine; Adrenergic Agents; Adult; Cerebellum; Cognition; Double-Blind Method; Female; Glucose; Hallucinogens; Humans; Magnetic Resonance Imaging; Male; Methamphetamine; Middle Aged; Nootropic Agents; Psilocybin; Psychopathology; Radionuclide Imaging | 1999 |
"Ecstasy"-induced changes of cerebral glucose metabolism and their correlation to acute psychopathology. An 18-FDG PET study.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Cerebral Cortex; Double-Blind Method; Female; Fluorodeoxyglucose F18; Glucose; Humans; Male; Mental Disorders; Middle Aged; Psychological Tests; Radionuclide Imaging; Radiopharmaceuticals | 1999 |
Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans.
Topics: 3,4-Methylenedioxyamphetamine; Analysis of Variance; Brain; Cognition; Double-Blind Method; Humans; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Psychometrics; Statistics, Nonparametric; Stereoisomerism | 2001 |
Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Attention; Central Nervous System Stimulants; Double-Blind Method; Female; Hallucinogens; Humans; Male; Methamphetamine; Middle Aged; Psilocybin; Reaction Time; Space Perception; Visual Perception | 2002 |
Enantioselective quantitation of the ecstasy compound (R)- and (S)-N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma and urine.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Chromatography, High Pressure Liquid; Cross-Over Studies; Double-Blind Method; Humans; Male; Middle Aged; Pilot Projects; Reproducibility of Results; Spectrometry, Fluorescence; Stereoisomerism | 2003 |
130 other study(ies) available for 3,4-methylenedioxyamphetamine and 3,4-methylenedioxyethamphetamine
| Article | Year |
|---|---|
The frontier orbital phase angles: novel QSAR descriptors for benzene derivatives, applied to phenylalkylamine hallucinogens.
Topics: Hallucinogens; Humans; Models, Molecular; Molecular Conformation; Phenethylamines; Quantum Theory | 1998 |
Comparative investigation of disposition of 3,4-(methylenedioxy)methamphetamine (MDMA) in the rat and the mouse by a capillary gas chromatography-mass spectrometry assay based on perfluorotributylamine-enhanced ammonia positive ion chemical ionization.
Topics: 3,4-Methylenedioxyamphetamine; Ammonia; Animals; Dopamine; Fluorocarbons; Gas Chromatography-Mass Spectrometry; Male; Methamphetamine; Mice; Mice, Inbred Strains; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Rats, Sprague-Dawley; Species Specificity | 1992 |
Cytopathologic features indicative of 5-hydroxytryptamine axon degeneration are observed in rat brain after administration of d- and l-methylenedioxyamphetamine.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Axons; Brain; Designer Drugs; Isomerism; Neurotoxins; Prosencephalon; Rats; Serotonin | 1992 |
Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylenedioxymethamphetamine): assessment using quantitative autoradiography.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Autoradiography; Brain; Dopamine; Male; Mazindol; N-Methyl-3,4-methylenedioxyamphetamine; Neural Pathways; Norepinephrine; Paroxetine; Piperidines; Rats; Rats, Inbred Strains; Reference Values; Serotonin; Time Factors | 1991 |
Possible serotonergic and dopaminergic mediation of the N-ethyl-3,4-methylenedioxyamphetamine discriminative stimulus.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Designer Drugs; Discrimination Learning; Fenclonine; Male; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Serotonin; Serotonin; Serotonin Antagonists | 1991 |
Identification of metabolites of 3,4-methylenedioxymethamphetamine in rats.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Chromatography, High Pressure Liquid; Designer Drugs; Gas Chromatography-Mass Spectrometry; Inactivation, Metabolic; Injections, Subcutaneous; Male; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Rats, Inbred Strains | 1990 |
Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Hematocrit; Metabolic Clearance Rate; Rats; Rats, Inbred Strains; Stereoisomerism; Structure-Activity Relationship | 1990 |
Effects of N-ethyl-3,4-methylenedioxyamphetamine (MDE) on central serotonergic and dopaminergic systems of the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Brain; Corpus Striatum; Dopamine; Frontal Lobe; Hippocampus; Homovanillic Acid; Hydroxyindoleacetic Acid; Hypothalamus; Male; Rats; Rats, Inbred Strains; Serotonin; Tryptophan Hydroxylase; Tyrosine 3-Monooxygenase | 1987 |
Characterization of acute N-ethyl-3,4-methylenedioxyamphetamine (MDE) action on the central serotonergic system.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Analysis of Variance; Animals; Drug Interactions; Fluoxetine; Frontal Lobe; Hippocampus; Hydroxyindoleacetic Acid; Male; Monoamine Oxidase; Pargyline; Rats; Rats, Inbred Strains; Serotonin; Tryptophan Hydroxylase | 1989 |
Behavioral effects of (+-) 3,4-methylenedioxyamphetamine (MDA) and (+-) 3,4-methylenedioxymethamphetamine (MDMA) in the pigeon: interactions with noradrenergic and serotonergic systems.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Behavior, Animal; Columbidae; Conditioning, Operant; Dose-Response Relationship, Drug; Female; Ketanserin; Male; Metergoline; N-Methyl-3,4-methylenedioxyamphetamine; Norepinephrine; Prazosin; Reinforcement Schedule; Serotonin; Sympathetic Nervous System | 1989 |
Stimulus effects of N-monoethyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDE) and N-hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane (N-OH MDA) in rats trained to discriminate MDMA from saline.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamine; Amphetamines; Animals; Discrimination, Psychological; Dose-Response Relationship, Drug; Generalization, Stimulus; Male; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Rats, Inbred Strains | 1989 |
Prepulse inhibition of the acoustic startle response is disrupted by N-ethyl-3,4-methylenedioxyamphetamine (MDEA) in the rat.
Topics: 3,4-Methylenedioxyamphetamine; Acoustic Stimulation; Amphetamines; Analysis of Variance; Animals; Chemical Phenomena; Chemistry; Isomerism; Male; Rats; Rats, Inbred Strains; Reflex, Startle | 1989 |
'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA.
Topics: 3,4-Methylenedioxyamphetamine; Accidents; Adolescent; Adult; Amphetamines; Arrhythmias, Cardiac; Asthma; Chromatography, Gas; Female; Gas Chromatography-Mass Spectrometry; Heart Diseases; Humans; Male; N-Methyl-3,4-methylenedioxyamphetamine | 1987 |
A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives.
Topics: 3,4-Dihydroxyphenylacetic Acid; 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Brain; Corpus Striatum; Dopamine; Homovanillic Acid; Male; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Rats, Inbred Strains; Tryptophan Hydroxylase; Tyrosine 3-Monooxygenase | 1987 |
Acute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Brain Chemistry; Cerebral Cortex; Male; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Rats, Inbred Strains; Serotonin; Stereoisomerism; Synaptosomes | 1987 |
3,4-Methylenedioxyethylamphetamine (MDE), a novel analogue of MDMA, produces long-lasting depletion of serotonin in the rat brain.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Brain; Dopamine; Dose-Response Relationship, Drug; Male; N-Methyl-3,4-methylenedioxyamphetamine; Norepinephrine; Rats; Rats, Inbred Strains; Serotonin | 1987 |
Behavioral effects of N-ethyl-3,4-methylenedioxyamphetamine (MDE; "EVE").
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Discrimination, Psychological; Dose-Response Relationship, Drug; Legislation, Drug; Male; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Rats, Inbred Strains; Time Factors; United States | 1987 |
Stimulus properties of 1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Dextroamphetamine; Discrimination Learning; DOM 2,5-Dimethoxy-4-Methylamphetamine; Male; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Rats, Inbred Strains; Stereoisomerism | 1988 |
Stimulant and hallucinogenic behavioral profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxyamphetamine in rats.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Behavior, Animal; Hallucinogens; Male; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Rats, Inbred Strains; Time Factors | 1988 |
Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Biogenic Monoamines; Dopamine; Male; Methoxyhydroxyphenylglycol; Mice; N-Methyl-3,4-methylenedioxyamphetamine; Nervous System Diseases; Norepinephrine; Rats; Species Specificity | 1988 |
Ring-substituted amphetamine interactions with neurotransmitter receptor binding sites in human cortex.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Cerebral Cortex; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Receptors, Neurotransmitter | 1988 |
Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Discrimination, Psychological; Dopamine Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Generalization, Stimulus; Male; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Rats, Inbred Strains; Serotonin; Serotonin Antagonists; Time Factors | 1988 |
Ecstasy toxicity.
Topics: 3,4-Methylenedioxyamphetamine; Charcoal; Designer Drugs; Drug Overdose; Humans; Tablets | 1995 |
Methylenedioxyamphetamine: neurotoxic effects on serotonergic projections to brainstem nuclei in the rat.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Axonal Transport; Axons; Brain Stem; Designer Drugs; Fluoxetine; Immunohistochemistry; Male; Nerve Fibers; Neurotoxins; Prosencephalon; Rats; Rats, Sprague-Dawley; Serotonin | 1993 |
Enhanced cerebrovascular responsiveness to hypercapnia following depletion of central serotonergic terminals.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Antipyrine; Autoradiography; Brain; Cerebrovascular Circulation; Deoxyglucose; Hypercapnia; Male; Nerve Endings; Paroxetine; Rats; Rats, Sprague-Dawley; Serotonin; Tritium | 1995 |
High-pressure liquid chromatography/electrochemical detection method for monitoring MDA and MDMA in whole blood and other biological tissues.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Chromatography, High Pressure Liquid; Designer Drugs; Electrochemistry; Evaluation Studies as Topic; N-Methyl-3,4-methylenedioxyamphetamine | 1993 |
[Studies on the identification of psychotropic substances. IX. Preparation and various analytical data of reference standard of new psychotropic substances, N-ethyl methylenedioxyamphetamine, N-hydroxy methylenedioxyamphetamine, mecloqualone, 4-methylamin
Topics: 3,4-Methylenedioxyamphetamine; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Gas Chromatography-Mass Spectrometry; Morpholines; Oxazoles; Phenmetrazine; Psychotropic Drugs; Quinazolines; Spectrophotometry | 1993 |
Immunocytochemical evidence for serotonergic neurotoxicity of N-ethyl-methylenedioxyamphetamine (MDE).
Topics: 3,4-Methylenedioxyamphetamine; Animals; Brain; Cell Survival; Immunohistochemistry; Male; Neurons; p-Chloroamphetamine; Rats; Rats, Sprague-Dawley; Serotonin; Time Factors | 1994 |
A case of toxic psychosis induced by 'eve' (3,4-methylene-dioxyethylam-phetamine)
Topics: 3,4-Methylenedioxyamphetamine; Administration, Oral; Adult; Humans; Male; N-Methyl-3,4-methylenedioxyamphetamine; Psychoses, Substance-Induced; Substance-Related Disorders | 1993 |
"Ecstasy" and liver transplantation.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Female; Hallucinogens; Humans; Liver Failure, Acute; Liver Transplantation; Male | 1993 |
Two very different fatal cases associated with the use of methylenedioxyethylamphetamine (MDEA): Eve as deadly as Adam.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Designer Drugs; Fatal Outcome; Fever; Humans; Male; Psychoses, Substance-Induced; Suicide | 1996 |
[Epileptic insults, cerebral infarction and rhabdomyolysis as complications of amphetamine use].
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Cerebral Infarction; Designer Drugs; Epilepsy, Generalized; Humans; Male; Rhabdomyolysis; Substance-Related Disorders | 1996 |
Pathology of deaths associated with "ecstasy" and "eve" misuse.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Brain; Humans; Liver; Male; Myocardium; N-Methyl-3,4-methylenedioxyamphetamine; Substance-Related Disorders | 1996 |
"ADAM' or "EVE'?--a toxicological conundrum.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Amphetamine; Female; Homicide; Humans; Male; N-Methyl-3,4-methylenedioxyamphetamine | 1996 |
Use of drugs at 'raves'.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Catha; Central Nervous System Stimulants; Dancing; Designer Drugs; Female; Hallucinogens; Humans; Lysergic Acid Diethylamide; Male; N-Methyl-3,4-methylenedioxyamphetamine; Plant Extracts; Scotland; Substance-Related Disorders; Surveys and Questionnaires | 1995 |
Fatal poisoning by MDMA (ecstasy) and MDEA: a case report.
Topics: 3,4-Methylenedioxyamphetamine; Capillaries; Designer Drugs; Drug Overdose; Fluorescent Antibody Technique; Gas Chromatography-Mass Spectrometry; Hallucinogens; Humans; Kidney Tubules; Lung; Myoglobinuria; N-Methyl-3,4-methylenedioxyamphetamine; Poisoning; Pulmonary Embolism | 1996 |
Adam and Eve make love. Analysis of the enantiomers of 3,4-methylenedioxy-N-ethylamphetamine (MDE, "Eve") and its metabolite 3,4-methylenedioxyamphetamine (MDA) in rat brain.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Brain; Designer Drugs; Hallucinogens; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Stereoisomerism | 1996 |
Ecstasy and neurodegeneration. Advice is that "less is more".
Topics: 3,4-Methylenedioxyamphetamine; Chronic Disease; Designer Drugs; Humans; Nervous System Diseases; Risk Factors | 1996 |
Ecstasy and neurodegeneration. No evidence of neurotoxicity exists.
Topics: 3,4-Methylenedioxyamphetamine; Brain Diseases; Chronic Disease; Designer Drugs; Humans; Nervous System Diseases | 1996 |
Ecstasy and neurodegeneration. Tablets often contain substances in addition to, or instead of, ecstasy...
Topics: 3,4-Methylenedioxyamphetamine; Designer Drugs; Drug Contamination; Humans; Nervous System Diseases; Tablets | 1996 |
Ecstasy and neurodegeneration. ...such as ketamine.
Topics: 3,4-Methylenedioxyamphetamine; Designer Drugs; Drug Contamination; Ephedrine; Hallucinogens; Humans; Ketamine; Substance-Related Disorders; Tablets | 1996 |
Ecstasy and neurodegeneration. gamma-Hydroxybutyrate is a new recreational drug that may lead to loss of consciousness.
Topics: 3,4-Methylenedioxyamphetamine; Designer Drugs; Diagnosis, Differential; Humans; Seizures; Sodium Oxybate; Substance-Related Disorders; Unconsciousness | 1996 |
Concentrations of delta 9-tetrahydrocannabinol, cocaine and 6-monoacetylmorphine in hair of drug abusers.
Topics: 3,4-Methylenedioxyamphetamine; Accidents, Traffic; Amphetamine; Cocaine; Crime; Designer Drugs; Dronabinol; Expert Testimony; Gas Chromatography-Mass Spectrometry; Hair; Heroin Dependence; Humans; Illicit Drugs; Marijuana Abuse; Morphine Derivatives; N-Methyl-3,4-methylenedioxyamphetamine; Opioid-Related Disorders; Psychotropic Drugs; Sensitivity and Specificity | 1996 |
Acute poisoning with amphetamines (MDEA) and heroin: antagonistic effects between the two drugs.
Topics: 3,4-Methylenedioxyamphetamine; Acute Disease; Adult; Confusion; Critical Care; Designer Drugs; Drug Antagonism; Drug Monitoring; Heroin; Humans; Male; Narcotics; Suicide, Attempted; Time Factors | 1996 |
[Acute fatal poisoning caused by methylenedioxyamphetamine].
Topics: 3,4-Methylenedioxyamphetamine; Adult; Designer Drugs; Fatal Outcome; Humans; Male | 1996 |
Metabolism of racemic 3,4-methylenedioxyethylamphetamine in humans. Isolation, identification, quantification, and synthesis of urinary metabolites.
Topics: 3,4-Methylenedioxyamphetamine; Chromatography, High Pressure Liquid; Gas Chromatography-Mass Spectrometry; Humans; Magnetic Resonance Spectroscopy; Reference Values; Reproducibility of Results; Spectrophotometry, Infrared; Stereoisomerism | 1996 |
Some examples of the analysis of complex samples by micellar electrokinetic capillary chromatography with photodiode array detection.
Topics: 3,4-Methylenedioxyamphetamine; Alkaloids; Buffers; Chromatography, Liquid; Coloring Agents; Electrophoresis, Capillary; Micelles; Morphine; Spectrophotometry, Ultraviolet | 1996 |
Toxicological detection of the designer drug 3,4-methylenedioxyethylamphetamine (MDE, "Eve") and its metabolites in urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay.
Topics: 3,4-Methylenedioxyamphetamine; Administration, Oral; Amphetamines; Deoxyepinephrine; Designer Drugs; Dopamine; Fluorescence Polarization Immunoassay; Gas Chromatography-Mass Spectrometry; Hallucinogens; Humans; Time Factors | 1996 |
Chronic ecstasy (3,4-methylenedioxymetamphetamine) abuse: a recurrent and unpredictable cause of severe acute hepatitis.
Topics: 3,4-Methylenedioxyamphetamine; Acute Disease; Adolescent; Adult; Biopsy; Chemical and Drug Induced Liver Injury; Female; Humans; Male; Recurrence; Substance-Related Disorders | 1996 |
Quantitative and qualitative analysis of MDMA, MDEA, MA and amphetamine in urine by headspace/solid phase micro-extraction (SPME) and GC/MS.
Topics: 3,4-Methylenedioxyamphetamine; Gas Chromatography-Mass Spectrometry; Hallucinogens; Humans; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine | 1996 |
[Psychiatric disorders after a single 3,4-methylenedioxyethamphetamine (MDE, "Eve") and tetrahydrocannabinol (cannabis) use].
Topics: 3,4-Methylenedioxyamphetamine; Adult; Designer Drugs; Dronabinol; Drug Synergism; Female; Humans; Psychoses, Substance-Induced | 1996 |
Hair analysis for drug abuse. XV. Disposition of 3, 4-methylenedioxymethamphetamine (MDMA) and its related compounds into rat hair and application to hair analysis for MDMA abuse.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Gas Chromatography-Mass Spectrometry; Hair; Hallucinogens; Humans; Lactates; Male; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Substance Abuse Detection; Substance-Related Disorders | 1997 |
[Epidemiology of designer drug use in Spain].
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Cocaine; Designer Drugs; Female; Heroin; Humans; Male; N-Methyl-3,4-methylenedioxyamphetamine; Prevalence; Spain; Substance-Related Disorders | 1997 |
Ecstasy: creatinine kinase.
Topics: 3,4-Methylenedioxyamphetamine; Creatine Kinase; Dantrolene; Designer Drugs; Fever; Humans; Multiple Organ Failure; Muscle Relaxants, Central; Muscle, Skeletal; N-Methyl-3,4-methylenedioxyamphetamine; Paraplegia | 1997 |
Sensitive and selective determination of methylenedioxylated amphetamines by high-performance liquid chromatography with fluorimetric detection.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Chromatography, High Pressure Liquid; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Substance Abuse Detection; Tablets | 1997 |
On acute poisoning with amphetamines.
Topics: 3,4-Methylenedioxyamphetamine; Acute Disease; Designer Drugs; Heroin; Humans; Narcotic Antagonists; Narcotics; Substance-Related Disorders | 1998 |
Ion trap mass spectrometry for the characterization of N-methyl-1- (3,4-methylene-dioxyphenyl)-2-butanamine and N-ethyl-3,4- methylenedioxyamphetamine, two widely distributed street drugs.
Topics: 3,4-Methylenedioxyamphetamine; Designer Drugs; Gas Chromatography-Mass Spectrometry; Illicit Drugs | 1998 |
Intentional overdose and death with 3,4-methylenedioxyethamphetamine (MDEA; "Eve"): case report.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Chromatography, Gas; Designer Drugs; Drug Overdose; Fatal Outcome; Female; Gas Chromatography-Mass Spectrometry; Humans; Suicide | 1998 |
Detection of designer drugs in human hair by ion mobility spectrometry (IMS).
Topics: 3,4-Methylenedioxyamphetamine; Designer Drugs; Forensic Medicine; Hair; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Sensitivity and Specificity; Spectrometry, Mass, Secondary Ion; Substance-Related Disorders | 1998 |
The acute effect in rats of 3,4-methylenedioxyethamphetamine (MDEA, "eve") on body temperature and long term degeneration of 5-HT neurones in brain: a comparison with MDMA ("ecstasy").
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Brain; Cerebral Cortex; Dose-Response Relationship, Drug; Fever; Hippocampus; Male; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Endings; Paroxetine; Rats; Serotonin; Time Factors; Visual Cortex | 1999 |
Simultaneous determination of amphetamine, methamphetamine, methylenedioxyamphetamine (MDA), methylenedioxymethamphetamine (MDMA), and methylenedioxyethylamphetamine (MDEA) enantiomers by GC-MS.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Central Nervous System Stimulants; Gas Chromatography-Mass Spectrometry; Humans; In Vitro Techniques; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Sensitivity and Specificity; Stereoisomerism; Substance Abuse Detection; Time Factors; Urine | 1999 |
Adam (MDMA) and Eve (MDEA) misuse: an immunohistochemical study on three fatal cases.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Disseminated Intravascular Coagulation; Fatal Outcome; Forensic Medicine; Gas Chromatography-Mass Spectrometry; Hallucinogens; Humans; Male; Myoglobinuria; N-Methyl-3,4-methylenedioxyamphetamine; Rhabdomyolysis | 1999 |
Serotonergic deficits and impaired passive-avoidance learning in rats by MDEA: a comparison with MDMA.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Avoidance Learning; Carrier Proteins; Designer Drugs; Frontal Lobe; Hippocampus; Male; Membrane Glycoproteins; Membrane Transport Proteins; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Tissue Proteins; Paroxetine; Rats; Rats, Wistar; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Agents; Serotonin Plasma Membrane Transport Proteins | 2000 |
The use of supercritical fluid extraction for the determination of amphetamines in hair.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Designer Drugs; Gas Chromatography-Mass Spectrometry; Hair; Humans; Illicit Drugs; N-Methyl-3,4-methylenedioxyamphetamine; Reference Values; Reproducibility of Results; Substance Abuse Detection; Substance-Related Disorders | 2000 |
Automated determination of 'Ecstasy' and amphetamines in urine by SPME and capillary gas chromatography after propylchloroformate derivatisation.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Designer Drugs; Esters; Evaluation Studies as Topic; Formates; Gas Chromatography-Mass Spectrometry; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Reproducibility of Results; Sensitivity and Specificity; Substance Abuse Detection | 1999 |
High-resolution solid state 13C nuclear magnetic resonance spectra of 3,4-methylenedioxyamphetamine hydrochloride and related compounds and their mixtures with lactose.
Topics: 3,4-Methylenedioxyamphetamine; Carbon Isotopes; Crystallization; Ephedrine; Hydrogen Bonding; Lactose; Magnetic Resonance Spectroscopy; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Solutions; Stereoisomerism | 2000 |
Determination of the designer drugs 3, 4-methylenedioxymethamphetamine, 3,4-methylenedioxyethylamphetamine, and 3,4-methylenedioxyamphetamine with HPLC and fluorescence detection in whole blood, serum, vitreous humor, and urine.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Chromatography, High Pressure Liquid; Designer Drugs; Humans; Mass Spectrometry; N-Methyl-3,4-methylenedioxyamphetamine; Rabbits; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Substance Abuse Detection; Vitreous Body | 2000 |
Identification of the nitrogen-based blister agents bis(2-chloroethyl)methylamine (HN-2) and tris(2-chloroethyl)amine (HN-3) and their hydrolysis products on soil using ion trap secondary ion mass spectrometry.
Topics: 3,4-Methylenedioxyamphetamine; Chemical Warfare Agents; Ethanolamines; Hydrolysis; Irritants; Mechlorethamine; Nitrogen Mustard Compounds; Soil; Spectrometry, Mass, Secondary Ion | 2000 |
Stereospecific analysis of ecstasy-like N-ethyl-3,4-methylenedioxyamphetamine and its metabolites in humans.
Topics: 3,4-Methylenedioxyamphetamine; Chromatography, High Pressure Liquid; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Sensitivity and Specificity | 2001 |
Alterations in diurnal and nocturnal locomotor activity in rats treated with a monoamine-depleting regimen of methamphetamine or 3,4-methylenedioxymethamphetamine.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Biogenic Monoamines; Circadian Rhythm; Dopamine Agents; Male; Methamphetamine; Motor Activity; Rats; Rats, Sprague-Dawley | 2001 |
Danger: possibly fatal interactions between ritonavir and "ecstasy," some other psychoactive drugs.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamine; Cocaine; Drug Interactions; Fatal Outcome; Hallucinogens; Heroin; HIV Protease Inhibitors; Humans; Illicit Drugs; Male; Methadone; Ritonavir | 1997 |
Ecstasy and ritonavir.
Topics: 3,4-Methylenedioxyamphetamine; Analgesics, Opioid; Drug Interactions; Hallucinogens; HIV Protease Inhibitors; Humans; Male; Methadone; Ritonavir | 1997 |
Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Biogenic Monoamines; Brain; Dopamine; Fever; Locomotion; Male; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Rats, Wistar; Serotonin; Serotonin Agents | 2001 |
Sensitive determination of methylenedioxylated amphetamines by liquid chromatography.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Chromatography, Liquid; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine | 2001 |
Stability study of the designer drugs "MDA, MDMA and MDEA" in water, serum, whole blood, and urine under various storage temperatures.
Topics: 3,4-Methylenedioxyamphetamine; Chromatography, High Pressure Liquid; Designer Drugs; Drug Stability; Drug Storage; Forensic Medicine; N-Methyl-3,4-methylenedioxyamphetamine; Reproducibility of Results; Water | 2001 |
Application of SERS spectroscopy to the identification of (3,4-methylenedioxy)amphetamine in forensic samples utilizing matrix stabilized silver halides.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamine; Illicit Drugs; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Spectrum Analysis, Raman | 2001 |
Quantitation of amphetamine, methamphetamine, and their methylenedioxy derivatives in urine by solid-phase microextraction coupled with electrospray ionization-high-field asymmetric waveform ion mobility spectrometry-mass spectrometry.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamine; Central Nervous System Stimulants; Hallucinogens; Humans; Indicators and Reagents; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Spectrometry, Mass, Electrospray Ionization; Substance Abuse Detection | 2002 |
Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect?
Topics: 3,4-Methylenedioxyamphetamine; Adrenergic Uptake Inhibitors; Animals; Catalepsy; Dopamine Antagonists; Dose-Response Relationship, Drug; Haloperidol; Male; N-Methyl-3,4-methylenedioxyamphetamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 2002 |
Developmental 3,4-methylenedioxymethamphetamine (MDMA) impairs sequential and spatial but not cued learning independent of growth, litter effects or injection stress.
Topics: 3,4-Methylenedioxyamphetamine; Adrenocorticotropic Hormone; Aging; Animals; Animals, Newborn; Behavior, Animal; Body Constitution; Body Weight; Case-Control Studies; Corticosterone; Cues; Excitatory Amino Acid Agonists; Female; Learning Disabilities; Litter Size; Male; Maze Learning; Parity; Random Allocation; Rats; Rats, Sprague-Dawley; Reaction Time; Serial Learning; Sex Factors; Spatial Behavior; Stress, Physiological; Swimming; Time Factors | 2003 |
Development of a rapid and sensitive method for the quantitation of amphetamines in human plasma and oral fluid by LC-MS-MS.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamine; Amphetamines; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Chromatography, Liquid; Ephedrine; Humans; Mass Spectrometry; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Reproducibility of Results; Saliva; Substance Abuse Detection | 2003 |
Is the Ecstasy-induced ipsilateral rotation in 6-hydroxydopamine unilaterally lesioned rats dopamine independent?
Topics: 3,4-Methylenedioxyamphetamine; Adrenergic Agents; Animals; Apomorphine; Behavior, Animal; Citalopram; Dopamine; Fenclonine; Functional Laterality; Hallucinogens; Male; Medial Forebrain Bundle; Models, Animal; N-Methyl-3,4-methylenedioxyamphetamine; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rotation; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 2003 |
Actions of amphetamine derivatives and cathinone at the noradrenaline transporter.
Topics: 3,4-Methylenedioxyamphetamine; Adrenergic Uptake Inhibitors; Alkaloids; Amphetamines; Animals; Cerebral Cortex; Cocaine; Competitive Bidding; Fluoxetine; In Vitro Techniques; Male; Myocardium; N-Methyl-3,4-methylenedioxyamphetamine; Norepinephrine Plasma Membrane Transport Proteins; Rats; Rats, Wistar; Symporters | 2003 |
Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity.
Topics: 3,4-Methylenedioxyamphetamine; Drug Combinations; Drug Contamination; Hallucinogens; History, 20th Century; History, 21st Century; Illicit Drugs; N-Methyl-3,4-methylenedioxyamphetamine; Tablets | 2004 |
Application of ORAL.screen saliva drug test for the screening of methamphetamine, MDMA, and MDEA incorporated in hair.
Topics: 3,4-Methylenedioxyamphetamine; Forensic Medicine; Hair; Humans; Immunoassay; Immunochemistry; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Reagent Kits, Diagnostic; Saliva; Substance Abuse Detection | 2004 |
Determination of MDMA, MDEA and MDA in urine by high performance liquid chromatography with fluorescence detection.
Topics: 3,4-Methylenedioxyamphetamine; Chromatography, High Pressure Liquid; Forensic Medicine; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 2004 |
Enantiomeric separation and quantitation of (+/-)-amphetamine, (+/-)-methamphetamine, (+/-)-MDA, (+/-)-MDMA, and (+/-)-MDEA in urine specimens by GC-EI-MS after derivatization with (R)-(-)- or (S)-(+)-alpha-methoxy-alpha-(trifluoromethy)phenylacetyl chlor
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Chromatography, Gas; Chromatography, Ion Exchange; Humans; Indicators and Reagents; Methamphetamine; Military Personnel; N-Methyl-3,4-methylenedioxyamphetamine; Quaternary Ammonium Compounds; Reference Standards; Spectrometry, Mass, Electrospray Ionization; Stereoisomerism; Substance Abuse Detection | 2004 |
Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) exposure induces long-term alterations in the dopaminergic and serotonergic functions in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; 3,4-Methylenedioxyamphetamine; Adrenergic Uptake Inhibitors; Age Factors; Analysis of Variance; Animals; Animals, Newborn; Autoradiography; Brain; Brain Chemistry; Dopamine; Embryo, Mammalian; Female; Fenfluramine; Hallucinogens; Homovanillic Acid; Hydroxyindoleacetic Acid; Male; Membrane Transport Proteins; Microdialysis; Nortropanes; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin; Sex Factors; Time Factors; Tyramine | 2005 |
Amphetamine toxicity in the emergency department.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Amphetamines; Emergency Service, Hospital; Fatal Outcome; Female; Humans; Male; Substance-Related Disorders | 2005 |
Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for enantioselective measurement of the designer drugs MDEA, MDMA, and MDA and its application to samples from a controlled study with MDMA.
Topics: 3,4-Methylenedioxyamphetamine; Dose-Response Relationship, Drug; Gas Chromatography-Mass Spectrometry; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Sensitivity and Specificity; Stereoisomerism; Substance Abuse Detection; Time Factors | 2005 |
An announced suicide with ecstasy.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Austria; Autopsy; Drug Combinations; Drug Overdose; Forensic Toxicology; Humans; Male; N-Methyl-3,4-methylenedioxyamphetamine; Suicide | 2007 |
LC-MS/MS in the elucidation of an isomer of the recreational drug methylenedioxy ethylamphetamine: methylenedioxy dimethylamphetamine.
Topics: 3,4-Methylenedioxyamphetamine; Calibration; Chromatography, Liquid; Illicit Drugs; Indicators and Reagents; Isomerism; Mass Spectrometry; Models, Molecular; Molecular Structure; Spectrometry, Fluorescence | 2005 |
Development and application of a high-performance liquid chromatography method using monolithic columns for the analysis of ecstasy tablets.
Topics: 3,4-Methylenedioxyamphetamine; Chromatography, High Pressure Liquid; Hallucinogens; N-Methyl-3,4-methylenedioxyamphetamine; Reference Standards; Reproducibility of Results; Spectrophotometry, Ultraviolet; Tablets; Technology, Pharmaceutical | 2006 |
Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve alpha-adrenoceptors.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Aorta; Blood Pressure; Body Temperature; Heart Rate; Imidazoles; Indoles; Isoindoles; Male; Motor Activity; Muscle Contraction; Muscle, Smooth; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Rats, Wistar; Receptors, Adrenergic, alpha; Time Factors; Vas Deferens | 2006 |
Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994-2003).
Topics: 3,4-Methylenedioxyamphetamine; Amphetamine-Related Disorders; Cause of Death; Crime; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug and Narcotic Control; Humans; Illicit Drugs; N-Methyl-3,4-methylenedioxyamphetamine; Statistics as Topic; United Kingdom | 2006 |
Chiral separation and quantification of R/S-amphetamine, R/S-methamphetamine, R/S-MDA, R/S-MDMA, and R/S-MDEA in whole blood by GC-EI-MS.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamine; Chromatography, Gas; Humans; Methamphetamine; Molecular Structure; N-Methyl-3,4-methylenedioxyamphetamine; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Stereoisomerism; Substance Abuse Detection | 2006 |
Clozapine reverses increased brown adipose tissue thermogenesis induced by 3,4-methylenedioxymethamphetamine and by cold exposure in conscious rats.
Topics: 3,4-Methylenedioxyamphetamine; Adipose Tissue, Brown; Animals; Body Temperature; Clozapine; Cold Temperature; Consciousness; GABA Antagonists; Intestines; Male; Rats; Rats, Sprague-Dawley; Thermogenesis; Time Factors | 2006 |
Sensitive gas chromatography-mass spectrometry method for simultaneous measurement of MDEA, MDMA, and metabolites HMA, MDA, and HMMA in human urine.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Calibration; Central Nervous System Stimulants; Dopamine; Gas Chromatography-Mass Spectrometry; Humans; Hydrolysis; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Sensitivity and Specificity; Substance Abuse Detection | 2006 |
Time-resolved hair analysis of MDMA enantiomers by GC/MS-NCI.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamine; Biomarkers; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Gas Chromatography-Mass Spectrometry; Hair; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Substance Abuse Detection; Time Factors | 2007 |
Analysis of MDMA and its metabolites in urine and plasma following a neurotoxic dose of MDMA.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Biotransformation; Calibration; Dopamine; Gas Chromatography-Mass Spectrometry; Male; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Psychotropic Drugs; Rats; Reproducibility of Results; Toxicology | 2007 |
Simultaneous analysis of six amphetamines and analogues in hair, blood and urine by LC-ESI-MS/MS. Application to the determination of MDMA after low ecstasy intake.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Amphetamines; Chromatography, Liquid; Female; Forensic Toxicology; Hair; Hallucinogens; Humans; Spectrometry, Mass, Electrospray Ionization; Substance Abuse Detection | 2007 |
Validated liquid chromatographic-electrospray ionization mass spectrometric assay for simultaneous determination of 3,4-methylenedioxymethamphetamine and its metabolites 3,4-methylenedioxyamphetamine, 3,4-dihydroxymethamphetamine, and 4-hydroxy-3-methoxym
Topics: 3,4-Methylenedioxyamphetamine; Animals; Calibration; Chromatography, Liquid; Deoxyepinephrine; Hallucinogens; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Saimiri; Spectrometry, Mass, Electrospray Ionization | 2007 |
Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma.
Topics: 3,4-Methylenedioxyamphetamine; Calibration; Central Nervous System Stimulants; Dopamine; Gas Chromatography-Mass Spectrometry; Humans; Hydrolysis; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Reproducibility of Results; Substance Abuse Detection | 2008 |
The effect of long-term repeated exposure to 3,4-methylenedioxymethamphetamine on cardiovascular and thermoregulatory changes.
Topics: 3,4-Dihydroxyphenylacetic Acid; 3,4-Methylenedioxyamphetamine; Animals; Behavior, Animal; Body Temperature Regulation; Cerebral Cortex; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Heart Rate; Hot Temperature; Humans; Hydroxyindoleacetic Acid; Hyperthermia, Induced; Injections, Intraperitoneal; Male; Motor Activity; Rats; Rats, Sprague-Dawley; Serotonin; Telemetry; Time Factors | 2008 |
Impact of plasticity and flexibility on docking results for cytochrome P450 2D6: a combined approach of molecular dynamics and ligand docking.
Topics: 3,4-Methylenedioxyamphetamine; Catalytic Domain; Chlorpromazine; Computer Simulation; Coumarins; Cytochrome P-450 CYP2D6; Ligands; Models, Chemical; Molecular Structure; Propranolol; Stereoisomerism; Tamoxifen | 2008 |
Simultaneous determination of methamphetamine, 3,4-methylenedioxy-N-methylamphetamine, 3,4-methylenedioxy-N-ethylamphetamine, N,N-dimethylamphetamine, and their metabolites in urine by liquid chromatography-electrospray ionization-tandem mass spectrometry
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Chromatography, High Pressure Liquid; Humans; Hydrogen-Ion Concentration; Indicators and Reagents; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization | 2008 |
The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxyethylamphetamine and its single enantiomers.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamine; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Designer Drugs; Gas Chromatography-Mass Spectrometry; Humans; Isoenzymes; Microsomes, Liver; Stereoisomerism; Substrate Specificity | 2009 |
Determination of the metabolites of the new designer drugs bk-MBDB and bk-MDEA in human urine.
Topics: 3,4-Methylenedioxyamphetamine; Designer Drugs; Forensic Toxicology; Gas Chromatography-Mass Spectrometry; Hallucinogens; Humans; Hydrolysis; Methylation | 2009 |
Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation.
Topics: 3,4-Methylenedioxyamphetamine; Biocatalysis; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cytochrome P-450 Enzyme System; Designer Drugs; Dopamine; Enzyme Inhibitors; Gas Chromatography-Mass Spectrometry; Humans; Kinetics; Methylation; Microsomes, Liver; N-Methyl-3,4-methylenedioxyamphetamine; Stereoisomerism | 2009 |
Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Female; Gas Chromatography-Mass Spectrometry; Hallucinogens; Humans; Male; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Substance Abuse Detection; Young Adult | 2009 |
Role of water in molecular docking simulations of cytochrome P450 2D6.
Topics: 3,4-Methylenedioxyamphetamine; Catalytic Domain; Cytochrome P-450 CYP2D6; Molecular Dynamics Simulation; Reproducibility of Results; Water | 2010 |
GC-MS studies on side chain regioisomers related to substituted methylenedioxyphenethylamines: MDEA, MDMMA, and MBDB.
Topics: 3,4-Methylenedioxyamphetamine; Gas Chromatography-Mass Spectrometry; Illicit Drugs; Molecular Conformation; Molecular Weight; Stereoisomerism | 2010 |
Hair MDMA samples are consistent with reported ecstasy use: findings from a study investigating effects of ecstasy on mood and memory.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Affect; Female; Hair; Humans; Illicit Drugs; Internet; Male; Marijuana Smoking; Memory; Self Medication; Self Report; Substance Abuse Detection; Surveys and Questionnaires | 2011 |
Differences in binding affinities of MDA, MDMA, MDEA, Amphetamine, Methamphetamine, and their deuterated analogues to solid-phase extraction cartridges.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamine; Deuterium; Gas Chromatography-Mass Spectrometry; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Solid Phase Extraction; Substance Abuse Detection | 2011 |
Inhibition of 3,4-methylenedioxymethamphetamine metabolism leads to marked decrease in 3,4-dihydroxymethamphetamine formation but no change in serotonin neurotoxicity: implications for mechanisms of neurotoxicity.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Deoxyepinephrine; Dextromethorphan; Excitatory Amino Acid Antagonists; Hydroxyindoleacetic Acid; Male; Neurotoxicity Syndromes; Neurotoxins; Rats; Rats, Sprague-Dawley; Serotonin; Sulfides | 2011 |
Simultaneous determination of HFBA-derivatized amphetamines and ketamines in urine by gas chromatography-mass spectrometry.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Fluorocarbons; Gas Chromatography-Mass Spectrometry; Humans; Illicit Drugs; Ketamine; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Solid Phase Extraction; Substance Abuse Detection | 2011 |
A comparison of the validity of gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry analysis of urine samples II: amphetamine, methamphetamine, (±)-3,4-methylenedioxyamphetamine, (±)-3,4-methylenedioxymethamphetamine, (
Topics: 3,4-Methylenedioxyamphetamine; Amphetamine; Chromatography, High Pressure Liquid; Dronabinol; Gas Chromatography-Mass Spectrometry; Illicit Drugs; Methamphetamine; Phencyclidine; Reproducibility of Results; Substance Abuse Detection; Tandem Mass Spectrometry | 2010 |
Molecularly imprinted solid-phase extraction for the selective determination of methamphetamine, amphetamine, and methylenedioxyphenylalkylamine designer drugs in human whole blood by gas chromatography-mass spectrometry.
Topics: 3,4-Methylenedioxyamphetamine; Adsorption; Amphetamine; Amphetamines; Designer Drugs; Gas Chromatography-Mass Spectrometry; Humans; Molecular Imprinting; Polymers; Solid Phase Extraction | 2012 |
New chlorinated amphetamine-type-stimulants disinfection-by-products formed during drinking water treatment.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Central Nervous System Stimulants; Disinfection; Drinking Water; Halogenation; N-Methyl-3,4-methylenedioxyamphetamine; Spain; Spectrometry, Mass, Electrospray Ionization; Water Purification; Water Quality | 2012 |
Investigations on the stereoselectivity of the phase II metabolism of the 3,4-methylenedioxyethylamphetamine (MDEA) metabolites 3,4-dihydroxyethylamphetamine (DHEA) and 4-hydroxy-3-methoxyethylamphetamine (HMEA).
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Designer Drugs; Gas Chromatography-Mass Spectrometry; Humans; Liver; Microsomes, Liver; Rats; Stereoisomerism; Sulfotransferases | 2012 |
Effects of stress and MDMA on hippocampal gene expression.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Gene Expression Regulation; Hippocampus; Neurotoxicity Syndromes; Protein Biosynthesis; Protein Folding; Rats; Serotonin; Serotonin Agents; Stress Disorders, Post-Traumatic | 2014 |
Molecular basis of the selective binding of MDMA enantiomers to the alpha4beta2 nicotinic receptor subtype: synthesis, pharmacological evaluation and mechanistic studies.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Binding Sites; Dose-Response Relationship, Drug; Molecular Structure; PC12 Cells; Rats; Receptors, Nicotinic; Stereoisomerism; Structure-Activity Relationship | 2014 |
Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process.
Topics: 3,4-Methylenedioxyamphetamine; Amiodarone; Animals; Antiviral Agents; Cell Line; Ebolavirus; Humans; Microbial Sensitivity Tests; Virus Internalization | 2015 |
Screening for illicit drugs in pooled human urine and urinated soil samples and studies on the stability of urinary excretion products of cocaine, MDMA, and MDEA in wastewater by hyphenated mass spectrometry techniques.
Topics: 3,4-Methylenedioxyamphetamine; Adrenergic Uptake Inhibitors; Cocaine; Dopamine Uptake Inhibitors; Environmental Pollutants; Humans; Illicit Drugs; Limit of Detection; N-Methyl-3,4-methylenedioxyamphetamine; Soil; Substance Abuse Detection; Wastewater | 2017 |
Tunability of Biodegradable Poly(amine- co-ester) Polymers for Customized Nucleic Acid Delivery and Other Biomedical Applications.
Topics: 3,4-Methylenedioxyamphetamine; 3T3 Cells; Animals; Decanoic Acids; Dicarboxylic Acids; Esters; Gene Transfer Techniques; HEK293 Cells; Humans; Macrolides; Mice; Nanoparticles; Polyamines; Polymerization | 2018 |
A Gas Chromatography-Mass Spectrometry Method for Toxicological Analysis of MDA, MDEA and MDMA in Vitreous Humor Samples from Victims of Car Accidents.
Topics: 3,4-Methylenedioxyamphetamine; Accidents, Traffic; Driving Under the Influence; Forensic Toxicology; Gas Chromatography-Mass Spectrometry; Humans; Limit of Detection; N-Methyl-3,4-methylenedioxyamphetamine; Postmortem Changes; Reproducibility of Results; Vitreous Body | 2018 |
Emergency Embolization of Artery of Adamkiewicz Pseudoaneurysm Following Methylenedioxymethamphetamine Abuse.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Aneurysm, False; Arteries; Computed Tomography Angiography; Embolization, Therapeutic; Humans; Magnetic Resonance Imaging; Male; Subarachnoid Hemorrhage; Substance-Related Disorders; Tomography Scanners, X-Ray Computed | 2019 |
Serotonin syndrome unmasking thyrotoxicosis.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Aftercare; Anti-Arrhythmia Agents; Antithyroid Agents; Carbimazole; Delirium; Diagnosis, Differential; Humans; Intensive Care Units; Male; Propranolol; Serotonin Syndrome; Substance-Related Disorders; Thyrotoxicosis; Thyrotropin; Treatment Outcome; Tremor | 2019 |
[High-risk drug use: epidemiological pattern through hair testing in the forensic context].
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Amphetamine; Cannabinoids; Cocaine; Cross-Sectional Studies; Female; Forensic Sciences; Gas Chromatography-Mass Spectrometry; Hair; Heroin; Humans; Illicit Drugs; Ketamine; Male; Methadone; Methamphetamine; Middle Aged; N-Methyl-3,4-methylenedioxyamphetamine; Prevalence; Spain; Substance Abuse Detection; Substance-Related Disorders; Young Adult | 2019 |
Interaction Profiles of Central Nervous System Active Drugs at Human Organic Cation Transporters 1-3 and Human Plasma Membrane Monoamine Transporter.
Topics: 3,4-Methylenedioxyamphetamine; Cell Line; Central Nervous System; Citalopram; Dopamine Plasma Membrane Transport Proteins; Equilibrative Nucleoside Transport Proteins; GABA Plasma Membrane Transport Proteins; HEK293 Cells; Humans; Octamer Transcription Factors; Organic Cation Transporter 1; Organic Cation Transporter 2; Psychotropic Drugs; Pyrrolidines; Serotonin Plasma Membrane Transport Proteins; Vesicular Monoamine Transport Proteins | 2021 |
CO
Topics: 3,4-Methylenedioxyamphetamine; Carbon Dioxide; Ethanolamines; Thiophenes; Water | 2022 |